1268244-75-2

Upstream product

• 1268246-55-4 2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]benzaldehyde 
• 1268245-50-6 4-(chloromethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole 
• 946426-89-7 4-(hydroxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1263281-96-4 C₁₇H₁₅ClO₃ 
• 1268245-10-8 (-)-3-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 
• 1020569-65-6 ethyl 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylate 
• 67853-03-6 methyl 3-(hydroxymethyl)benzoate 
• 550377-89-4 4-{[tert-butyl(dimethyl)silyl]oxy}-2-chlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 1459-93-4 dimethyl Isophthalate 
• 96534-02-0 3-(diethyoxyphosphorylmethyl)benzoic acid methyl ester 

Relevant academic research and scientific papers

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties

Several isoxazole-containing series of FXR agonists have been published over the last 15 years, subsequent to the prototypical amphiphilic ‘hammerhead’-type structure that was originally laid out by GW4064, the first potent synthetic FXR agonist. A set of novel compounds where the hammerhead is connected to the terminal carboxylic acid-bearing aryl or heteroaryl moiety by either a cyclopropyl, a hydroxycyclobutyl or a hydroxyazetidinyl linker was synthesized in order to improve upon the ADME properties of such isoxazoles. The resulting compounds all demonstrated high potencies at the target receptor FXR but with considerable differences in their physicochemical and in vivo profiles. The structure–activity relationships for key chemical features that have a major impact on the in vivo pharmacology of this series are discussed.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.